RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and MicroRNA expression signatures.

ABSTRACT:

Purpose

To determine the association of RUNX1 mutations with therapeutic outcome in younger and older patients with primary cytogenetically normal acute myeloid leukemia (CN-AML) and with gene/microRNA expression signatures.

Patients and methods

Younger (< 60 years; n = 175) and older (≥ 60 years; n = 225) patients with CN-AML treated with intensive cytarabine/anthracycline-based first-line therapy on Cancer and Leukemia Group B protocols were centrally analyzed for RUNX1 mutations by polymerase chain reaction and direct sequencing and for established prognostic gene mutations. Gene/microRNA expression profiles were derived using microarrays.

Results

RUNX1 mutations were found in 8% and 16% of younger and older patients, respectively (P = .02). They were associated wi

SUBMITTER: Mendler JH 

PROVIDER: S-EPMC3732007 | biostudies-literature | 2012 Sep

REPOSITORIES: biostudies-literature